Featured news from NHIVNA
HIV-related news from NAM
High incidence of HCV re-infection among HIV-positive MSM in Western Europe
Michael Carter, 2016-04-19 10:00:00
There is a very
high incidence of hepatitis C virus (HCV) re-infection among HIV-positive men
who have sex with men (MSM) in western Europe, according to research presented
to the International Liver Congress in Barcelona. Investigators found that a
quarter of HIV-positive MSM who cleared an initial HCV infection were re-infected
with HCV within three years. The researchers believe that current prevention
strategies are failing and call for the intensive monitoring of people who
have apparently cleared an HCV infection.
There are ongoing
HCV epidemics among HIV-positive MSM in many industrialised countries. There is
convincing evidence of sexual transmission, with unprotected anal sex, fisting
and re-use of injecting equipment identified as high-risk activities. A recent meta-analysis
suggested that prevalence of HCV co-infection among HIV-positive MSM is between
5 and 6%.
HCV infection can
be cured with therapy and spontaneous clearance of acute infection has also been documented.
in Amsterdam and London has found a high incidence of HCV re-infection after
successful treatment or spontaneous clearance. There are several reasons why it
is important to establish a clearer understanding of the incidence of
re-infection and its risk factors, including prevention and screening
strategies. Moreover, re-infection could affect the cost/benefit of expensive,
but highly effective new therapies.
the UK, Germany, Austria and France therefore designed a study to estimate the
incidence of HCV re-infection among HIV-positive MSM who cleared the virus either
after therapy or spontaneously.
population consisted of 606 men with confirmed cure or spontaneous clearance.
Patients who received therapy were considered cured if they had a negative HCV
PCR twelve weeks after the completion of therapy; cure following spontaneous
clearance was a negative HCV PCR result 24 weeks after the first negative PCR.
collected on age, date of HCV diagnosis, HCV genotype, HCV and HIV viral load,
use of antiretroviral therapy (ART), CD4 count and liver function (maximum ALT). Data were also
requested on presence of the IL28B gene – associated with favourable outcomes –
but response rates were poor.
defined as a positive HCV PCR after confirmed cure/spontaneous clearance.
Over three years
of follow-up, 149 patients (24.6%) were re-infected. The median time to
re-infection was 1.8 years. Median age at the time of re-infection was 41
years. Most individuals – 91 of 111 patients with available data – had an
undetectable HIV viral load at the time of re-infection and median CD4 cell
count was 533 cells/mm3.
clearance of the initial infection was observed in 15%
of patients after re-infection. 113 people received antiviral treatment, of whom 87 were cured.
re-infection was recorded in 29 patients, four patients were re-infected three
times and a single individual had four re-infections.
Just over a
quarter (29%) of patients spontaneously cleared their second re-infection and a
third experienced spontaneous clearance of their third re-infection.
of re-infection was 7.6 per 100 person-years. Incidence of second
was even higher at 19.9 per 100 person years.The incidence of
reinfection was markedly higher in Paris (21.8 per 100 p.y.) and Vienna
(16.8 per 100 p.y.) than in London (7 per 100 p.y. ) and German centres
(5-8 per 100 p.y.) but the amount of patient follow-up available for
analysis makes it difficult to draw firm conclusions.
clearance of the initial infection was associated with a significant reduction
in the risk of re-infection (HR = 0.55; 95% CI, 0.32-0.95) and also the chances
of spontaneous clearance if re-infected (OR = 12.7; 95% CI, 2.3-70.2).
conclude that there is a substantial risk of HCV re-infection for HIV-positive
MSM. They believe their results show the failure of current prevention
interventions and underline the need for new strategies. The researchers also
suggest their findings have implications for the monitoring of co-infected MSM
and call for HCV PCR testing to be performed every three to six months after HCV
infection and every three months after re-infection.